The chairman of the Clinical Advisory Committee of the New England Chapter of the National MS Society addressed the role DMTs play in patient response to the COVID-19 vaccine.
Joshua Katz, MD
Advertisement
Codirector, Elliot Lewis Center for Multiple Sclerosis Care, assistant professor, neurology, Tufts University School of Medicine, and chairman, Clinical Advisory Committee, New England Chapter, National MS Society
Articles by Joshua Katz, MD
The codirector of the Elliot Lewis Center for Multiple Sclerosis Care discussed the prospective COVID-19 vaccination booster and its implication for patients with MS.
Advertisement
Latest Updated Articles
The Potential COVID-19 Booster for Patients With MS: Joshua Katz, MDPublished: September 10th 2021 | Updated:
- Disease-Modifying Therapies and COVID-19 Antibody Response: Joshua Katz, MD
Published: September 12th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency
2
New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment
3
New Study to Assess Complement Inhibitor Iptacopan in Generalized Myasthenia Gravis
4
Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS
5
